Court Ruling Paves Way Ackman To Have His Way With Allergan

HFA Padded
Mark Melin
Published on
Updated on

Allergan, Inc. (NYSE:AGN) is much closer to being a very changed company after a judge ruled in favor of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) and Bill Ackman’s Pershing Square Capital Management. “We now expect Allergan to more aggressively consider its alternatives including a possible friendly deal with another pharmaceutical company or an acquisition of its own,” Shibani Malhotra, an analyst at Sterne Agee & Leach Inc., was quoted as saying in a Bloomberg report. Allergan likely available at the right price Sources close to the situation have noted that Allergan, Inc. (NYSE:AGN) is likely available, at the right price.  In…

This content is exclusively for paying members of Hedge Fund Alpha

Log In

Insider Strategies and Letters to Shareholders from the Top Hedge Funds and Maximize Your Portfolio Growth with Hedge Fund Alpha

Don’t have an account?

Subscribe now and get 7 days free!

HFA Padded

Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.